Catalysts
VRTX Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
VRTXVertex Pharmaceuticals Incorporated
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum83
- Value70
- Quality71
- Risk resilience80
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 83/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 36.33%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | — | $4.82 | $4.76 | -1.2% | $3.42B | $3.44B |
| Aug 3, 2026 | — | $4.74 | $4.73 | -0.2% | $3.23B | $3.33B |
| May 4, 2026 | — | $4.24 | $4.47 | +5.4% | $2.99B | $2.99B |
| Feb 12, 2026 | — | $5.11 | $5.03 | -1.6% | $3.18B | $3.19B |
| Nov 3, 2025 | — | $4.57 | $4.80 | +5.0% | $3.06B | $3.08B |
| Aug 4, 2025 | — | $4.29 | $4.52 | +5.4% | $2.91B | $2.96B |
| May 5, 2025 | — | $4.25 | $4.06 | -4.5% | $2.86B | $2.77B |
| Feb 10, 2025 | — | $4.02 | $3.98 | -1.0% | $2.78B | $2.91B |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members with Appointment of Former Boston Scientific CFO Daniel Brennan
Vertex Pharmaceuticals Incorporated (VRTX) announced that Daniel Brennan has been appointed as a new member of its board of directors, effective October 20, 20
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an
Related Links
VRTX Catalysts FAQ
What are the next catalysts for VRTX stock?
VRTX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move VRTX stock?
Upcoming events that could move VRTX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could VRTX's next earnings report affect the stock?
VRTX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive VRTX stock higher?
VRTX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt VRTX stock?
VRTX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.